BriaCell Therapeutics Corp. (BCTX)
- Previous Close
2.1100 - Open
2.0000 - Bid 1.4400 x 200
- Ask 2.4300 x 200
- Day's Range
1.8700 - 2.0000 - 52 Week Range
1.8700 - 7.5900 - Volume
89,990 - Avg. Volume
68,065 - Market Cap (intraday)
31.45M - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7900 - Earnings Date Jun 10, 2024 - Jun 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
briacell.comRecent News: BCTX
Performance Overview: BCTX
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCTX
Valuation Measures
Market Cap
33.44M
Enterprise Value
27.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
17.03
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-85.45%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.61M
Diluted EPS (ttm)
-0.7900
Balance Sheet and Cash Flow
Total Cash (mrq)
6.24M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-19.76M
Research Analysis: BCTX
Company Insights: BCTX
BCTX does not have Company Insights